+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Hemoglobinopathies Drug"

Hemoglobinopathies - Global Strategic Business Report - Product Thumbnail Image

Hemoglobinopathies - Global Strategic Business Report

  • Report
  • May 2024
  • 192 Pages
  • Global
From
From
From
From
From
From
From
  • 18 Results (Page 1 of 1)
Loading Indicator

Hemoglobinopathies are a group of inherited blood disorders caused by abnormal hemoglobin production. Hemoglobin is the protein in red blood cells that carries oxygen throughout the body. Hemoglobinopathies can cause anemia, fatigue, and other health problems. Treatment for hemoglobinopathies typically involves medications to increase red blood cell production, reduce symptoms, and prevent complications. The hemoglobinopathies drug market is a subset of the hematological drugs market. It includes drugs used to treat hemoglobinopathies, such as hydroxyurea, decitabine, and l-glutamine. These drugs are used to reduce the severity of symptoms, increase red blood cell production, and prevent complications. Companies in the hemoglobinopathies drug market include Novartis, Pfizer, GlaxoSmithKline, Merck, and Sanofi. These companies produce and market drugs used to treat hemoglobinopathies. Show Less Read more